Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders.
Researchers from Flavii Therapeutics SL and collaborators presented preclinical data on FLAV-27, a G9a inhibitor designed to target G9a-mediated epigenetic dysregulation.
Mindbeam AI has leveraged generative AI to accelerate the discovery of novel pain therapeutics predicted to have improved liver safety compared to acetaminophen.
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has announced the teams for the THRIVE (Treating Hereditary Rare diseases with In Vivo prEcision genetic medicines) program. With a commitment of up to $160 million over 5 years, THRIVE aims to accelerate solutions for rare genetic pediatric diseases across multiple technological approaches, clinical trial designs and deployment models.
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent Astrazeneca plc’s shares (NYSE:AZN) down $10.88 to close July 9 at $178.40.
Niagen Bioscience Inc. has announced the initiation of a program targeting accelerated aging and rare genetic diseases, with the development by subsidiary NAD Pharmaceuticals Corp. of its first drug candidate, NB-4168.
Researchers at the University of South Florida have focused on the demyelination hallmark of traumatic brain injury (TBI) and have tested a liver X receptor (LXR) agonist, GW-3965, for the potential treatment of it. Activation of LXRs is known to support oligodendrocyte maturation, increase myelin gene expression and promote remyelination.
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development, according to presentations at the FENS Forum 2026.
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience meeting – a symposium on ectodomain shedding showcased how soluble synaptic proteins are emerging as both biomarkers and therapeutic candidates for disorders ranging from autism to schizophrenia.
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system.
RSS
